Syndax Pharmaceuticals In...

AI Score

0

Unlock

14.23
-0.13 (-0.91%)
At close: Jan 29, 2025, 3:59 PM
14.24
0.04%
After-hours Jan 29, 2025, 04:00 PM EST
undefined%
Bid 13.63
Market Cap 1.22B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -3.64
PE Ratio (ttm) -3.91
Forward PE n/a
Analyst Buy
Ask 14.5
Volume 1,379,962
Avg. Volume (20D) 2,360,610
Open 14.28
Previous Close 14.36
Day's Range 14.07 - 14.56
52-Week Range 12.06 - 25.34
Beta undefined

About SNDX

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that b...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 2, 2016
Employees 184
Stock Exchange NASDAQ
Ticker Symbol SNDX

Analyst Forecast

According to 10 analyst ratings, the average rating for SNDX stock is "Buy." The 12-month stock price forecast is $37, which is an increase of 159.92% from the latest price.

Buy 90.00%
Hold 10.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Syndax Pharmaceuticals Inc. is scheduled to release its earnings on Feb 25, 2025, during market hours.
Analysts project revenue of $21.98M, reflecting a n/a YoY growth and earnings per share of -1.07, making a 7.00% increase YoY.
2 months ago
-25.57%
Syndax Pharmaceuticals shares are trading lower. T... Unlock content with Pro Subscription
6 months ago
-10.21%
Syndax Pharmaceuticals shares are trading lower after the FDA extended the review period for the company's leukemia drug Revumenib.